These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7927152)

  • 1. Health care innovation: progress report and focus on biotechnology.
    Read JL; Lee KB
    Health Aff (Millwood); 1994; 13(3):215-25. PubMed ID: 7927152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical innovation meets healthcare reform.
    White JH
    Health Prog; 1994; 75(6):14-6, 32. PubMed ID: 10135162
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of the private sector in biotechnology: research and development.
    Feisee L
    Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359
    [No Abstract]   [Full Text] [Related]  

  • 4. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anatomy of medical research: US and international comparisons.
    Moses H; Matheson DH; Cairns-Smith S; George BP; Palisch C; Dorsey ER
    JAMA; 2015 Jan; 313(2):174-89. PubMed ID: 25585329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care reform and the pharmaceutical industry.
    Mossinghoff GJ
    Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sticking to the knitting: CIHR, innovation and Canadian biotech.
    Edelson J
    Healthc Q; 2005; 8(3):65-8. PubMed ID: 16078405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A venture capital view of challenges, opportunities, and innovation in biomedical research.
    Ratcliffe LT
    Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovation and compliance are not diametrically opposed.
    Raab GK
    Qual Assur; 1994 Mar; 3(1):2-8. PubMed ID: 7804614
    [No Abstract]   [Full Text] [Related]  

  • 11. Financial anatomy of neuroscience research.
    Dorsey ER; Vitticore P; De Roulet J; Thompson JP; Carrasco M; Johnston SC; Holloway RG; Moses H
    Ann Neurol; 2006 Dec; 60(6):652-9. PubMed ID: 17192926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What health reform means for innovation.
    Nat Biotechnol; 2010 Apr; 28(4):293. PubMed ID: 20379152
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical entrepreneurism: the current opportunity in America.
    Lexa FJ
    J Am Coll Radiol; 2004 Oct; 1(10):762-8. PubMed ID: 17411697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care reform: impact on R&D and innovation in the biotechnology industry.
    Lerner TL
    Ann N Y Acad Sci; 1994 Nov; 729():128-31. PubMed ID: 7998724
    [No Abstract]   [Full Text] [Related]  

  • 15. The significance of health care reform for research, innovations, and academic medicine.
    Pardes H
    Ann N Y Acad Sci; 1994 Nov; 729():132-8; discussion 139-42. PubMed ID: 7998725
    [No Abstract]   [Full Text] [Related]  

  • 16. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 17. Building a life sciences innovation ecosystem.
    Harrison KD; Kadaba NS; Kelly RB; Crawford D
    Sci Transl Med; 2012 Oct; 4(157):157fs37. PubMed ID: 23100622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotechnology: delivering on the promise.
    Greenwood JC
    Sci Transl Med; 2010 Jan; 2(13):13cm1. PubMed ID: 20371460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotech sector ponders potential 'bloodbath'.
    Mitchell P
    Nat Biotechnol; 2009 Jan; 27(1):3-4. PubMed ID: 19131974
    [No Abstract]   [Full Text] [Related]  

  • 20. Financing development stage biotechnology companies: RMs vs. IPOs.
    Ahn MJ; Couch RB; Wu W
    J Health Care Finance; 2011; 38(1):32-54. PubMed ID: 22043645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.